RA'ANANA, Israel, Jan. 27,
2025 /PRNewswire/ -- Inspira Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira," or the
"Company"), a leader in innovative medical technology, has
announced the addition of new support features to the INSPIRA™
ART100, a system cleared by the U.S. Food and Drug Administration.
These enhancements are designed to assist medical team procedures
to reduce staff overhead and improve efficiency, further
solidifying Inspira's position at the forefront of extracorporeal
life support technology.
The new features provide valuable resources for clinical teams
using the system within its intent of use. For example, the system
is designed to integrate a given hospital's established procedures
and safety practices and includes system-activated alarm
troubleshooting uniquely designed to provide valuable direction
when time is of the essence and user anxiety is running high. The
system also provides a prominent screen with advanced software that
displays information in an accessible and visible manner during
complicated and challenging care situations – for example when the
patient is isolated or in-transit.
These new features are intended to further support staff using
the INSPIRA ART100's existing advanced and cutting-edge software
already designed to navigate the staff through a step-by-step setup
process, demonstrating another example of Inspira's dedication
through innovation to assist medical teams to manage complex
medical procedures more effectively.
"Our goal is to develop systems that support medical
professionals in their work to treat patients and save lives", said
Dagi Ben-Noon, Chief Executive Officer of Inspira. "These
additions reflect our commitment to being pioneers in the life
support sector."
The INSPIRA ART100 system utilizes a technique that adds oxygen
to the blood and removes carbon dioxide, with the enriched blood
being circulated back to the patient, taking over the functionality
of the heart and/or lungs in critical care patients. The INSPIRA
ART100 has a small footprint design, provides up to four hours of
uptime in emergency scenarios, and can be used with various types
of disposable equipment available on the market.
Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
targeting to better the life support and respiratory treatment
arena. The Company is developing a breakthrough Augmented
Respiration Technology (INSPIRA™ ART), a groundbreaking device
poised to revolutionize and potentially replace the $19 billion mechanical ventilation market. With
20 million intensive care unit patients with acute respiratory
failure each year, many of whom rely on mechanical ventilators, the
INSPIRA ART offers a potential alternative by elevating and
stabilizing decreasing oxygen saturation levels in minutes without
a ventilator, with patients being awake during treatment. The
INSPIRA ART is being designed to include the clip-on
HYLA™ blood sensor, a real-time continuous blood monitoring
technology, aiming to alert physicians of changes in a patient's
condition without the need for intermittent actual blood samples,
aiming to support physicians in making informed decisions.
In May and July 2024,
respectively, the Company's INSPIRA™ ART100 system has obtained FDA
510(k) clearance for use in CBP procedures, along with the Israeli
AMAR certification for both Extra-Corporeal Membrane Oxygenation
and Cardiopulmonary Bypass procedures.
The Company's other products and technologies, including the
INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the
INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen
Delivery System, and HYLA™ blood sensor, are currently being
designed and developed, and have not yet been tested or used in
humans nor approved by any regulatory entity.
For more information, please visit our corporate website at
https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements are based on the current expectations of
the management of the Company only and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
For example, the Company is using forward-looking statements when
it discusses the intended function and utility of the new support
features, its goal to further develop systems that support medical
professionals in their work to treat patients and save lives, and
its commitment to being pioneers in the life support sector. These
forward-looking statements and their implications are based solely
on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2023,
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website at www.sec.gov.
Contact: Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD.,
All rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-introduces-advanced-features-for-inspira-art100-further-amplifying-user-and-system-support-302360736.html
SOURCE Inspira Technologies
